Sera Prognostics, Inc. (SERA): Capital Expenditures

Annual figures by period end, from SEC filings.

$726.0K
Year ended 2025-12-31
$466.0K
Trailing 12 months to 2026-06-30
-2.8%
3-year compound annual growth
+37.3%
5-year compound annual growth
$1.30M2020-12-31: $149.0K2021-12-31: $1.30M2022-12-31: $791.0K2023-12-31: $128.0K2024-12-31: $56.0K2025-12-31: $726.0K$726.0K
2020-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$726.0Kn/m2026-03-18, From 2025-01-01
2024-12-31$56.0K-56.3%2026-03-18, From 2024-01-01
2023-12-31$128.0K-83.8%2025-03-19, From 2023-01-01
2022-12-31$791.0K-39.3%2024-03-20, From 2022-01-01
2021-12-31$1.30M+775.2%2023-03-22, From 2021-01-01
2020-12-31$149.0Kn/a2022-03-29, From 2020-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Sera Prognostics, Inc. (SERA)2025-12-31$726.0Kn/m
Aclarion, Inc. (ACON)2025-12-31$21.5K+320.9%
YD Bio Ltd (YDES)2025-12-31$1.44Mn/m
BioNexus Gene Lab Corp (BGLC)2025-12-31$37.0K-83.7%
American Shared Hospital Services (AMS)2025-12-31$7.63M-3.8%
CapForce Inc. (CFOR)2025-12-31$50.0Kn/a
Exagen Inc. (XGN)2025-12-31$641.0K+24.5%
Personalis, Inc. (PSNL)2025-12-31$4.50M+181.0%
Biodesix Inc (BDSX)2025-12-31$259.0K-92.0%

Compare SERA, ACON, YDES, BGLC side by side · Screen every company in Services-Medical Laboratories ↗